Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2401–2424 of 33,183 matching trials from the live ClinicalTrials.gov search.
Conditions
Hip Fracture, Myocardial Ischemia, Inflammation
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
65 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
New York, New York
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Metronidazole Drug Interaction Study With MMX® Mesalazine/Mesalamine

NCT01418365
Conditions
Healthy
Interventions
Metronidazole + MMX Mesalazine/mesalamine placebo, Metronidazole + MMX Mesalazine/mesalamine
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Lenexa, Kansas
Conditions
Delirium
Interventions
IV acetaminophen & IV propofol, IV acetaminophen & IV dexmedetomidine, IV propofol & placebo, IV dexmedetomidine & placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
60 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Terminated Phase 2 Interventional Results available

Etanercept for the Treatment of Lupus Nephritis

NCT00447265
Conditions
Lupus Nephritis
Interventions
Etanercept, Lupus Treatment- Standard of Care, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 3 more
Conditions
Primary Biliary Cholangitis
Interventions
Seladelpar 10 mg, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
43
States / cities
Chandler, Arizona • Pasadena, California • Sacramento, California + 32 more
Conditions
Foot Ulcer, Diabetic
Interventions
Engensis (VM202), Placebo
Genetic · Drug
Lead sponsor
Helixmith Co., Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 17 more
Conditions
Ulcerative Colitis
Interventions
PF-06826647 100 mg QD, PF-06826647 300 mg QD, PF-06826647 600 mg QD, Placebo, PF-6826647 400 mg QD
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
24
States / cities
Canoga Park, California • Inglewood, California • Newport Beach, California + 12 more
Terminated Phase 4 Interventional Results available

Vitamin D Deficiency in Patients With Hypertension

NCT00974922
Conditions
Vitamin D Deficiency, Hypertension
Interventions
Aliskiren, Cholecalciferol, Placebo
Drug · Dietary Supplement
Lead sponsor
UConn Health
Other
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Farmington, Connecticut
Conditions
Dental Research, Pharmaceutical Preparations, Dental
Interventions
oral dexamethasone, Placebo Oral Capsule
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
Recurrent UTIs, Recurrent Urinary Tract Infections, Recurrent Urinary Tract Infections in Women, Recurrent Urinary Tract Infection, Cystitis Recurrent, Cystitis Chronic, UTI, UTI - Urinary Tract Infection, UTI - Lower Urinary Tract Infection
Interventions
D-Mannose, Placebo
Dietary Supplement
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
55 Years to 85 Years · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Schizophrenia
Interventions
Cariprazine, Placebo
Drug
Lead sponsor
Gedeon Richter Plc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
9
States / cities
Culver City, California • Atlanta, Georgia • Bloomfield Hills, Michigan + 5 more
Conditions
Thyroid Eye Disease, Graves Ophthalmopathy, Graves Orbitopathy, Thyroid Associated Ophthalmopathy, Endocrine System Diseases, Orbital Diseases, Proptosis, Eye Diseases
Interventions
LASN01, Placebo
Drug
Lead sponsor
Lassen Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
10
States / cities
Beverly Hills, California • Palo Alto, California • San Diego, California + 6 more
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Abuse Potential of Istradefylline

NCT02609477
Conditions
Drug Abuse
Interventions
Istradefylline, Phentermine 45 mg, Placebo
Drug · Other
Lead sponsor
Kyowa Kirin Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Recruiting Not applicable Interventional Accepts healthy volunteers

Blood Flow Restriction Therapy in Lower Limb Extensor Injuries

NCT04149977
Conditions
Lower Limb Injury
Interventions
Physical Therapy with pressure cuff, Physical Therapy with placebo pressure cuff
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
Ankylosing Spondylitis
Interventions
Secukinumab (75 mg), Secukinumab (150 mg), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
10
States / cities
Boise, Idaho • Cedar Rapids, Iowa • Portland, Oregon + 7 more
Completed Phase 2 Interventional Results available

The Role of Hormones in Postpartum Mood Disorders

NCT00001481
Conditions
Postpartum Depression
Interventions
Estradiol, Placebo, Progesterone, leuprolide acetate
Drug · Other
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 50 Years · Female only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Healthy Participants, Dyslipidemia
Interventions
AZD4954, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Glendale, California • Inverness, Florida • Jacksonville, Florida + 3 more
Conditions
Healthy
Interventions
ABT-126, Placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Glendale, California
Completed Not applicable Interventional Accepts healthy volunteers

Accuracy of Current Techniques in Quantifying Ketone Levels

NCT06909331
Conditions
Placebo - Control, Exogenous Ketone Salt
Interventions
Exogenous ketone salt, Placebo drink solution
Dietary Supplement
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 35 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Augusta, Georgia
Conditions
Schizophrenia
Interventions
AZD8529, Placebo to match AZD8529
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Phase 1Phase 2 Interventional Results available

Safety Study of Dantrolene in Subarachnoid Hemorrhage

NCT01024972
Conditions
Subarachnoid Hemorrhage, Cerebral Vasospasm
Interventions
Dantrolene, Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Worcester, Massachusetts
Conditions
Breast Cancer
Interventions
Enzalutamide, exemestane, Placebo (for enzalutamide)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
89
States / cities
Aurora, Colorado • Colorado Springs, Colorado • Lakewood, Colorado + 54 more
Completed Phase 2Phase 3 Interventional Results available

Tolcapone in Obsessive Compulsive Disorder

NCT03348930
Conditions
Obsessive-Compulsive Disorder
Interventions
Tolcapone 200 MG
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Moderate-to-Severe Atopic Dermatitis, Dermatitis, Dermatitis Atopic, Eczema, Skin Diseases, Skin, Diseases Genetic, Genetic, Diseases Inborn, Skin, Disease, Eczematous Skin, Hypersensitivity, Immediate, Hypersensitivity, Immune System Diseases, Dermatitis, Atopic
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years to 17 Years
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
36
States / cities
Birmingham, Alabama • Gilbert, Arizona • Bakersfield, California + 31 more